# FDA-Approved Dosing: Temozolomide & Bevacizumab for GBM

## üèõÔ∏è TEMOZOLOMIDE (TEMODAR) - FDA APPROVAL MARCH 15, 2005

### FDA-Approved Indication
**Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment**

### Phase 1: Concomitant Treatment (with Radiotherapy)
- **Dose**: 75 mg/m¬≤ PO once daily
- **Duration**: 42 days (up to 49 days if tolerated)
- **Concurrent**: With focal radiotherapy (60 Gy in 30 fractions)
- **Administration**: Take on empty stomach

### Phase 2: Maintenance Treatment (Adjuvant)
- **Start**: 4 weeks after completion of radiotherapy
- **Cycle 1**: 150 mg/m¬≤ PO daily √ó 5 days (28-day cycle)
- **Cycles 2-6**: 200 mg/m¬≤ PO daily √ó 5 days (if tolerated)
- **Total duration**: Up to 6 cycles

### FDA Safety Requirements
**Prerequisites for dosing:**
- ANC ‚â•1.5 √ó 10‚Åπ/L
- Platelet count ‚â•100 √ó 10‚Åπ/L
- Non-hematological toxicity ‚â§ Grade 1 (except alopecia, nausea, vomiting)

**Monitoring schedule:**
- **Concomitant phase**: Weekly CBC
- **Maintenance phase**: CBC on Day 1 and Day 22 of each cycle

**Pneumocystis pneumonia (PCP) prophylaxis:**
- Required during concomitant phase
- Continue until lymphopenia resolves to Grade 1 or less

### FDA Clinical Trial Results (EORTC 26981/22981)
- **Population**: 573 GBM patients
- **Design**: TMZ + RT (n=287) vs RT alone (n=286)
- **Primary outcome**: Overall survival benefit
- **Results**: 14.6 vs 12.1 months (HR: 0.63, P<0.0001)
- **Significance**: 37% reduction in risk of death

---

## üèõÔ∏è BEVACIZUMAB (AVASTIN) - FDA APPROVAL MAY 5, 2009

### FDA-Approved Indication
**Treatment of recurrent glioblastoma in adults** (accelerated approval 2009, regular approval December 5, 2017)

### FDA-Approved Dosing
- **Standard dose**: 10 mg/kg IV every 2 weeks
- **Administration**: IV infusion only (never push/bolus)
- **Duration**: Until disease progression or unacceptable toxicity

### FDA Infusion Protocol
- **First infusion**: 90 minutes
- **Second infusion**: 60 minutes (if first tolerated)
- **Subsequent infusions**: 30 minutes (if previous tolerated)

### FDA Clinical Trial Data
**Study AVF3708g (Single-arm trial)**
- **Population**: Previously treated GBM patients
- **Dose**: 10 mg/kg IV every 2 weeks
- **Results**: 25.9% response rate
- **Median duration of response**: 4.2 months

**Confirmatory Trial (BELOB)**
- **Population**: 432 patients with first progression
- **Design**: Bevacizumab 10 mg/kg + lomustine vs lomustine alone
- **Randomization**: 2:1 ratio
- **Outcome**: Confirmed efficacy for regular FDA approval

### FDA Safety Profile
**Black Box Warnings:**
1. Gastrointestinal perforation (0.3-2.4%)
2. Surgery and wound healing complications
3. Hemorrhage (including CNS hemorrhage)

**Common adverse reactions (‚â•20%):**
- Fatigue, hypertension, diarrhea, decreased appetite
- Proteinuria, nausea, hemorrhage, dysarthria

**GBM-specific safety concerns:**
- CNS hemorrhage: 2.5% Grade ‚â•3
- Arterial thromboembolic events: Higher risk in GBM patients

### FDA Surgery Guidelines
- **Pre-operative**: Stop ‚â•28 days before elective surgery
- **Post-operative**: Do not start until ‚â•28 days after surgery and full wound healing

---

## üö´ IMPORTANT FDA LIMITATIONS

### Bevacizumab NOT Approved For:
- Newly diagnosed GBM (Phase III trials failed to show OS benefit)
- Combination with temozolomide for newly diagnosed GBM
- Pediatric gliomas

### Key FDA Trial Failures
**AVAglio Trial**: Bevacizumab + standard RT/TMZ vs placebo + RT/TMZ
- **PFS benefit**: 10.6 vs 6.2 months ‚úì
- **OS benefit**: No significant improvement ‚úó
- **Result**: FDA did not approve for newly diagnosed GBM

**RTOG 0825 Trial**: Similar design and results
- **Confirmed**: PFS benefit without OS improvement
- **Conclusion**: Bevacizumab not standard for newly diagnosed patients

---

## üìã FDA DOSE MODIFICATIONS

### Temozolomide
**No dose reductions recommended during concomitant phase**
- **Dose interruptions**: Based on patient tolerance
- **Maintenance adjustments**: Reduce by 25-50 mg/m¬≤ for toxicity
- **Discontinue if**: Unable to tolerate 100 mg/m¬≤

### Bevacizumab
**No dose reductions recommended per FDA labeling**
- **Management approach**: Hold treatment for toxicity
- **Resume**: At same dose when toxicity resolves
- **Permanent discontinuation**: For severe/life-threatening events

---

## üéØ FDA-APPROVED TREATMENT ALGORITHM

### Newly Diagnosed GBM
1. **Surgery**: Maximal safe resection
2. **Concomitant phase**: TMZ 75 mg/m¬≤ + RT (6-7 weeks)
3. **Maintenance phase**: TMZ 150-200 mg/m¬≤ √ó 5 days/28 days (6 cycles)
4. **Bevacizumab**: NOT approved for this setting

### Recurrent GBM
1. **Consider surgery**: If appropriate
2. **Bevacizumab**: 10 mg/kg IV every 2 weeks (FDA-approved)
3. **Alternative**: TMZ retreatment (if ‚â•5 months from last dose)
4. **Clinical trials**: Always consider

---

## üìû FDA REPORTING REQUIREMENTS

### Adverse Event Reporting
- **Serious/unexpected AEs**: Report to FDA MedWatch
- **Pregnancy exposure**: Registry participation
- **Secondary malignancies**: Long-term monitoring

### REMS Programs
- **Temozolomide**: No REMS required
- **Bevacizumab**: No REMS required
- **Standard pharmacovigilance**: Applies to both

---

*Based on FDA Orange Book, prescribing information, and clinical review documents*
*Last FDA label updates: Temozolomide (2023), Bevacizumab (2022)*